Clinical Trial Update: Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma [Phase 1, Phase 2]

View source ↗

Summary

A clinical trial investigating an IDO inhibitor in combination with checkpoint inhibitors for metastatic melanoma has completed Phase 1/2 studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Checkpoint inhibitors (immune checkpoint inhibitors (PD-1/PD-L1/CTLA-4 inhibitors))
• IDO inhibitor (indoleamine 2,3-dioxygenase inhibitor)

Snippet

Sponsor: NewLink Genetics Corporation | Conditions: Metastatic Melanoma, Stage III Melanoma | Phase 1, Phase 2 | Status: COMPLETED